Medical Editor: John P. Cunha, DO, FACOEP
Rimactane (rifampin) is an antibiotic indicated for the treatment of pulmonary tuberculosis and for the treatment of asymptomatic carriers of N. meningitidis to eliminate meningococci from the nasopharynx. Rimactane is available in generic form. Common side effects of Rimactane include:
- stomach upset
- loss of appetite
- loss of coordination
- inability to concentrate
- mental confusion
- visual disturbances
- muscular weakness
- pain in extremities
- generalized numbness
- menstrual irregularities, and
- hypersensitivity reactions (itching, hives, rash, sore mouth or tongue, and conjunctivitis)
The adult dose of Rimactane to treat pulmonary tuberculosis is 600 mg (two 300-mg Capsules) in a single daily administration. The pediatric dose of Rimactane to treat pulmonary tuberculosis is 10 to 20 mg/kg, not to exceed 600 mg/day. Rimactane should be taken once daily, either one hour before or two hours after a meal. In the treatment of pulmonary tuberculosis, rifampin must be used in conjunction with at least one other antituberculous agent. Rimactane may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Rimactane; it is unknown how it would affect a fetus. Rimactane passes into breast milk. Consult your doctor before breastfeeding.
Our Rimactane (rifampin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Gastrointestinal disturbances such as heartburn, epigastric distress, anorexia, nausea, vomiting, gas, cramps, and diarrhea have been noted in some patients. Rarely, pseudomembranous enterocolitis has been reported. Headache, drowsiness, fatigue, ataxia, dizziness, inability to concentrate, mental confusion, visual disturbances, muscular weakness, fever, pains in extremities, generalized numbness, and menstrual disturbances have also been noted.
Hypersensitivity reactions have been reported. Encountered occasionally have been pruritus, urticaria, rash, pemphigoid reaction, eosinophilia, sore mouth, sore tongue, and exudative conjunctivitis.
Rarely, hepatitis or a shock-like syndrome with a hepatic involvement and abnormal liver function tests have been reported. Transient abnormalities in liver function tests (e.g., elevations in serum bilirubin, BSP, alkaline phosphatase, serum transaminases) have also been observed. The BSP test should be performed prior to the morning dose of rifampin to avoid false-positive results.
Thrombocytopenia, transient leukopenia, hemolytic anemia, and decreased hemoglobin have been observed. Thrombocytopenia has occurred when rifampin and ethambutol were administered concomitantly according to an intermittent dose schedule twice weekly and in high doses.
Elevations in BUN and serum uric acid have occurred. Rarely, hemolysis, hemoglobinuria, hematuria, renal insufficiency or acute renal failure have been reported and are generally considered to be hypersensitivity reactions. These have usually occurred during intermittent therapy or when treatment was resumed following intentional or accidental interruption of a daily dosage regimen and were reversible when rifampin was discontinued and appropriate therapy instituted.
Although rifampin has been reported to have an immunosuppressive effect in some animal experiments, available human data indicate that this has no clinical significance.
Read the entire FDA prescribing information for Rimactane (Rifamycin Capsules)